StockData
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. (MRKR) stock

MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.32+0.47 (+54.71%)

Close on Nov 19, 2026Market cap $22.01MP/E –Yield –

Marker Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Marker Therapeutics's free cash flow for the twelve months ending Mar 31, 2020 was -$18.75M. For fiscal 2019 it was -$18.66M.

Annual free cash flow

PeriodPeriod endValueChange
FY2019Dec 31, 2019-$18.66M–
FY2018Dec 31, 2018-$14.63M–
FY2017Dec 31, 2017-$8.44M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2020Mar 31, 2020-$4.20M–
Q4 FY2019Dec 31, 2019-$4.57M–
Q3 FY2019Sep 30, 2019-$5.72M–
Q2 FY2019Jun 30, 2019-$4.26M–
Q1 FY2019Mar 31, 2019-$4.10M–
Q2 FY2018Jun 30, 2018-$2.40M–
Q1 FY2018Mar 31, 2018-$2.35M–

More Marker Therapeutics figures

See a number that looks wrong?